|
Introduction
SELECT (the Selenium and Vitamin E Cancer Prevention Trial) is the largest-ever prostate cancer prevention trial. Previous studies suggest that selenium and vitamin E (alone or in combination) may reduce the risk of developing prostate cancer by 60 percent and 30 percent, respectively, but only a large clinical trial such as SELECT can confirm those initial findings.
SELECT began enrolling patients on August 22, 2001, and closed enrollment on June 24, 2004, with 35,534 participants. About 15 percent of the participants are African-American.
The study includes men 55 and older. African-American men, 50 and over, were eligible to enroll because prostate cancer strikes African-American men earlier and more often than white men. There are 435 SELECT sites throughout the United States, Puerto Rico, and Canada.
Coordinated by a network of researchers called the Southwest Oncology Group (SWOG), the study is sponsored by the National Cancer Institute (NCI).
SWOG maintains a Web page with information about SELECT 2, including a list of participating sites.
To get more information about SELECT or to locate a participating center, call 1-800-4-CANCER in the United States and Puerto Rico or 1-888-939-3333 in Canada. |
